FR21C1039I1 - - Google Patents

Info

Publication number
FR21C1039I1
FR21C1039I1 FR21C1039C FR21C1039I1 FR 21C1039 I1 FR21C1039 I1 FR 21C1039I1 FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 I1 FR21C1039 I1 FR 21C1039I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR21C1039I1 publication Critical patent/FR21C1039I1/fr
Application granted granted Critical
Publication of FR21C1039I2 publication Critical patent/FR21C1039I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR21C1039C 2014-05-15 2021-09-09 Composés destinés à traiter l'amyotrophie spinale Active FR21C1039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
FR21C1039I1 true FR21C1039I1 (de) 2021-10-15
FR21C1039I2 FR21C1039I2 (fr) 2022-09-02

Family

ID=53175048

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1039C Active FR21C1039I2 (fr) 2014-05-15 2021-09-09 Composés destinés à traiter l'amyotrophie spinale

Country Status (36)

Country Link
US (1) US9969754B2 (de)
EP (3) EP3143025B1 (de)
JP (1) JP6236173B2 (de)
KR (2) KR102213740B1 (de)
CN (1) CN106459092B (de)
AR (1) AR100442A1 (de)
AU (1) AU2015261046C1 (de)
BR (1) BR112016026205B1 (de)
CA (1) CA2948561C (de)
CL (1) CL2016002836A1 (de)
CR (1) CR20160518A (de)
DK (1) DK3143025T3 (de)
EA (2) EA202090486A3 (de)
ES (2) ES2761423T3 (de)
FR (1) FR21C1039I2 (de)
HR (2) HRP20230637T1 (de)
HU (2) HUE046491T2 (de)
IL (2) IL248653B (de)
LT (1) LTPA2021010I1 (de)
MA (2) MA51988A (de)
MX (1) MX371050B (de)
MY (1) MY174284A (de)
NL (1) NL301128I2 (de)
NO (1) NO2021035I1 (de)
NZ (1) NZ725008A (de)
PE (1) PE20170128A1 (de)
PH (1) PH12016502081A1 (de)
PL (2) PL3143025T3 (de)
PT (1) PT3143025T (de)
RS (1) RS59718B1 (de)
SG (1) SG11201609497TA (de)
SI (2) SI3663296T1 (de)
TW (1) TWI667239B (de)
UA (1) UA119670C2 (de)
WO (1) WO2015173181A1 (de)
ZA (1) ZA201607026B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142364A1 (es) 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
CA2915764A1 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (de) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Verbindungen zur behandlung von spinaler muskelatrophie
EP4249472A3 (de) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Verfahren zur modulation von rna-spleissen
CN108137601A (zh) * 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 用于治疗肌萎缩性侧索硬化症的化合物
WO2017080967A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
IL281633B (en) 2015-12-10 2022-07-01 Ptc Therapeutics Inc Methods for treating Huntington's disease
CN108137579B (zh) 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
EP3544435A4 (de) * 2016-11-28 2020-11-04 PTC Therapeutics, Inc. Verfahren zur modulation von rna-splicing
EP3634953B1 (de) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Verbindungen zur behandlung von morbus huntington
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
JP7075484B2 (ja) 2017-09-22 2022-05-25 エフ．ホフマン－ラ ロシュ アーゲー ７－（４，７－ジアザスピロ［２．５］オクタン－７－イル）－２－（２，８－ジメチルイミダゾ［１，２－ｂ］ピリダジン－６－イル）ピリド［１，２－ａ］ピリミジン－４－オン誘導体の製造方法
WO2019068604A1 (en) * 2017-10-03 2019-04-11 F. Hoffmann-La Roche Ag NEW TREATMENT OF ADM
CA3094703A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
MX2020014116A (es) 2018-06-27 2021-06-15 Reborna Biosciences Inc Agente profilactico o terapeutico para atrofia muscular espinal.
WO2020079203A1 (en) 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
EP3982970A1 (de) 2019-06-12 2022-04-20 F. Hoffmann-La Roche AG Neue behandlung von sma
US20220315607A1 (en) 2019-07-31 2022-10-06 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
CN116981674A (zh) 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 新的噻唑并嘧啶酮衍生物
EP4308578A2 (de) 2021-03-18 2024-01-24 F. Hoffmann-La Roche AG Verfahren zur herstellung von risdiplam
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
TW202423419A (zh) 2022-10-14 2024-06-16 美商建南德克公司 治療脊髓性肌肉萎縮症之方法
WO2024154148A1 (en) * 2023-01-21 2024-07-25 Harman Finochem Limited Process for preparation of risdiplam, novel intermediates, and process for preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710808A (pt) * 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
WO2010019243A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Methods for treating viral infections
EP2337609B1 (de) * 2008-08-14 2016-08-17 Cardiac Pacemakers, Inc. Leistungsbeurteilung und adaptierung einer akustischen kommunikationsverbindung
CA2861609C (en) * 2011-12-30 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PE20142364A1 (es) * 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
EP2872493B1 (de) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyl chinolin-2-on derivative zur behandlung von spinaler muskelatrophie
WO2017080967A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
IL248653A0 (en) 2017-01-31
BR112016026205B1 (pt) 2021-12-07
WO2015173181A1 (en) 2015-11-19
NO2021035I1 (no) 2021-09-10
JP2017515863A (ja) 2017-06-15
PE20170128A1 (es) 2017-03-16
HRP20230637T1 (hr) 2023-09-29
MA51988A (fr) 2021-01-20
HUE046491T2 (hu) 2020-03-30
EP4241772A3 (de) 2023-11-15
NL301128I1 (de) 2021-09-22
ZA201607026B (en) 2022-05-25
EA035068B1 (ru) 2020-04-23
PT3143025T (pt) 2019-12-03
PL3663296T3 (pl) 2023-08-07
CA2948561C (en) 2019-10-22
KR20170003687A (ko) 2017-01-09
MY174284A (en) 2020-04-01
ES2761423T3 (es) 2020-05-19
KR102213740B1 (ko) 2021-02-09
EP3143025A1 (de) 2017-03-22
JP6236173B2 (ja) 2017-11-22
ES2949660T3 (es) 2023-10-02
UA119670C2 (uk) 2019-07-25
MX2016014547A (es) 2017-02-23
TWI667239B (zh) 2019-08-01
PL3143025T3 (pl) 2020-03-31
EP3143025B1 (de) 2019-10-09
PH12016502081A1 (en) 2017-01-09
EP3663296A1 (de) 2020-06-10
SI3143025T1 (sl) 2020-01-31
US9969754B2 (en) 2018-05-15
EA202090486A3 (ru) 2020-08-31
EP4241772A2 (de) 2023-09-13
MA39995B1 (fr) 2019-11-29
AU2015261046C1 (en) 2019-07-25
BR112016026205A2 (pt) 2017-08-15
CL2016002836A1 (es) 2017-04-21
TW201609738A (zh) 2016-03-16
CA2948561A1 (en) 2015-11-19
EP3663296B1 (de) 2023-05-17
BR112016026205A8 (pt) 2021-07-20
KR102256013B1 (ko) 2021-05-26
CR20160518A (es) 2017-02-21
LTPA2021010I1 (de) 2021-10-11
EA201692280A1 (ru) 2018-07-31
IL270027B (en) 2020-08-31
HUS2100037I1 (hu) 2021-10-28
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
KR20210014219A (ko) 2021-02-08
AU2015261046B2 (en) 2019-04-18
MX371050B (es) 2020-01-14
SG11201609497TA (en) 2016-12-29
IL248653B (en) 2019-11-28
CN106459092B (zh) 2019-10-15
SI3663296T1 (sl) 2023-08-31
AR100442A1 (es) 2016-10-05
DK3143025T3 (da) 2019-12-09
FR21C1039I2 (fr) 2022-09-02
CN106459092A (zh) 2017-02-22
NZ725008A (en) 2019-11-29
RS59718B1 (sr) 2020-01-31
AU2015261046A1 (en) 2016-10-27
US20170197990A1 (en) 2017-07-13
NL301128I2 (nl) 2021-10-25

Similar Documents

Publication Publication Date Title
FR21C1039I1 (de)
BR112016022558A2 (de)
BR112016020776A2 (de)
BR112016021730A2 (de)
BR112016023047A2 (de)
BR112016016536A2 (de)
BR112016022474A2 (de)
BR112016027265A2 (de)
BR112016021661A2 (de)
BR112016022165A2 (de)
BR112016027071A2 (de)
BR112016021583A2 (de)
BR112016027638A2 (de)
BR112016026979A2 (de)
BR112016021941A2 (de)
BR112016016298A2 (de)
BR112016014434A2 (de)
BR112016015779A2 (de)
BR112016015645A2 (de)
BR112016027088A2 (de)
BR112016025669A2 (de)
BR112016021784A2 (de)
BR112016021098A2 (de)
BR112016020595A2 (de)
BR112016016149A2 (de)